Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PRME · NASDAQ · Biological Products, (No Diagnostic Substances)
$3.55−0.29 (−7.55%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Prime Medicine (PRME) · oqro.io/stocks/PRME · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
5%+ stake, activist · Stake as of Nov 12, 2026 · Filed Nov 13, 2026
Robert Nelsen disclosed a 8.4% stake in PRME and may seek to influence the companySource5%+ stake · Stake as of Sep 30, 2026 · Filed Nov 13, 2026
ARK Investment Management LLC now owns 5.5% of PRME as a passive investorSourceFund moves · Holdings as of Sep 30, 2026 (Q3 2026) · Filed Nov 13, 2026
ARK Investment Management disclosed an increased position in PRME for Q3 2026SourceFund moves · Holdings as of Jun 30, 2026 (Q2 2026) · Filed Aug 14, 2026
ARK Investment Management disclosed an increased position in PRME for Q2 2026SourceFund moves · Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 12, 2026
ARK Investment Management disclosed an increased position in PRME for Q1 2026SourceFund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 11, 2026
ARK Investment Management disclosed a reduced position in PRME for Q4 2025SourceFund moves · Holdings as of Sep 30, 2025 (Q3 2025) · Filed Nov 12, 2025
ARK Investment Management disclosed an increased position in PRME for Q3 2025SourceInsider trade · Traded Aug 1, 2025 · Filed Aug 5, 2025
10% owner purchased ~$4.95M of PRME shares in the open marketSourceInsider trade · Traded Aug 1, 2025 · Filed Aug 1, 2025
10% owner purchased ~$10M of PRME shares in the open marketSourceInsider trade · Traded Aug 1, 2025 · Filed Aug 1, 2025
10% owner purchased ~$10M of PRME shares in the open marketSourceInsider trade · Traded Aug 1, 2025 · Filed Aug 1, 2025
Director purchased ~$10M of PRME shares in the open marketSourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Jul 30, 2025
ARK Investment Management disclosed a reduced position in PRME for Q2 2025SourceInsider trade · Traded Jun 30, 2025 · Filed Jul 1, 2025
10% owner purchased ~$53K of PRME shares in the open marketSourceInsider trade · Traded Jun 23, 2025 · Filed Jun 23, 2025
10% owner purchased ~$45K of PRME shares in the open marketSourceInsider trade · Traded Jun 16, 2025 · Filed Jun 16, 2025
10% owner purchased ~$31K of PRME shares in the open marketSourceInsider trade · Traded Jun 11, 2025 · Filed Jun 12, 2025
10% owner purchased ~$34K of PRME shares in the open marketSourceInsider trade · Traded May 21, 2025 · Filed May 22, 2025
CEO purchased ~$147K of PRME shares in the open marketSourceInsider trade · Traded May 21, 2025 · Filed May 22, 2025
Officer purchased ~$113K of PRME shares in the open marketSourceInsider trade · Traded May 20, 2025 · Filed May 22, 2025
Officer purchased ~$24K of PRME shares in the open marketSourceFund moves · Holdings as of Mar 31, 2025 (Q1 2025) · Filed May 7, 2025
ARK Investment Management disclosed a reduced position in PRME for Q1 2025SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 4, 2025
ARK Investment Management disclosed a reduced position in PRME for Q4 2024SourceFund moves · Holdings as of Sep 30, 2024 (Q3 2024) · Filed Oct 31, 2024
ARK Investment Management disclosed a reduced position in PRME for Q3 2024Source